SCHOOL platform: Biophysical principles

SCHOOL platform for receptor signaling

SCHOOL concept: Learning from viruses

SCHOOL approach to sepsis, lung cancer, breast and pancreatic cancer, autoimmune diseases and others


Multichain Immune Recognition Receptor Signaling From Spatiotemporal Organizaiton to Human Disease



  • SignaBlok has been highlighted by Mass High Tech as a top company to watch
    Read more
  • SignaBlok targets $2.5M funding to treat lung, breast cancer
    Read more
  • SignaBlok aims to condense virus evolution, discover new drug solutions
    Read more
  • UMass research focuses on anti-clotting platform
    Read more


Alexander B. Sigalov, Ph.D.
President and Founder

Alexander B. Sigalov, Ph.D. has extensive academic and industry experience. As a scientist with more than 85 scientific publications in different fields of his expertise, Dr. Sigalov is world-renowned for his leadership in biophysics, immunology, and atherosclerosis.

In the ‘90s, Dr. Sigalov founded the AMW Biomed Company (Moscow, Russia) where he developed and marketed in Russia the first diagnostic kits for heart disease and stroke serving more than 80 institutional customers. AMW Biomed also commercialized human apolipoproteins and was the official supplier of these proteins to the DAKO Company in Denmark.

Prior to founding SignaBlok, Dr. Sigalov worked at Massachusetts Institute of Technology, where he discovered an unusual biophysical phenomenon, the homooligomerization of intrinsically disordered proteins. Later, as a faculty at the University of Massachusetts Medical School, he used this discovery to develop a novel model of receptor signaling, the Signaling Chain HOmoOLigomerization (SCHOOL) model, and the related concept of modulation of cell response.

Dr. Sigalov is the sole inventor of methods and compositions created through the SCHOOL platform that can be used to prevent or treat multiple serious diseases with unmet needs. He also developed integrated nanosystems for targeted delivery of drugs and imaging agents to macrophage-rich sites of disease in vivo.

Dr. Sigalov holds a Ph.D. in Organic Chemistry and M.S. in Chemistry from Moscow State University (Moscow, Russia).

- Understanding Nature. Improving Life.

Fact Sheet


Press Releases

  • SignaBlok Awarded NIH Grant to Test New Therapy for Rheumatoid Arthritis
    Read more
  • SignaBlok Wins NIH Grant to Advance New Technology for Atherosclerosis Imaging
    Read more
  • SignaBlok Achieves Key In Vivo Proof of Concept for Treatment of Cancer and Sepsis
    Read more
  • SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer
    Read more
  • SignaBlok Receives NCI Grant to Test New Approach to Lung Cancer Treatment
    Read more
  • SignaBlok Receives NIH Grant to Develop Targeted Imaging of Atherosclerosis
    Read more
  • SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis
    Read more